Key facts
- This page summarizes Bernard J. Zovighian's Form 4 filing for Edwards Lifesciences Corp (EW).
- 9 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 11 May 2026, 21:32.
Bernard J. Zovighian - 07 May 2026 Form 4 Insider Report for Edwards Lifesciences Corp (EW)
- Reporting relationship
- CEO, Director
- Issuer ticker
- EW
- Reported as of
- 07 May 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 11 May 2026, 21:32:42 UTC
- Prior SEC filing
- 05 May 2026
- Next SEC filing
- 12 May 2026
- Source filing
- View source filing
- Reporting owner signature
- Linda J. Park, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Bernard J. Zovighian filed Form 4 for Edwards Lifesciences Corp (EW) on 11 May 2026.
Change
- Previous filing in this sequence was filed on 05 May 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001665141
Primary reporting owner
Zovighian Bernard J
- Relationship
- CEO, Director
- Address
- ONE EDWARDS WAY, IRVINE
- Signature
- Linda J. Park, Attorney-in-Fact
- Signature date
- 11 May 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EW
transaction
Common Stock
Award
- Transaction value
- Shares
- +43,800
- Change %
- +55%
- Price
- $0.000000*
- Shares after
- 124,058
- Date
- 07 May 2026
- Ownership
- Direct
- Footnotes
- F1
EW
transaction
Common Stock
Tax liability
- Transaction value
- Shares
- -4,153
- Change %
- -3.3%
- Price
- $83.20*
- Shares after
- 119,905
- Date
- 07 May 2026
- Ownership
- Direct
EW
transaction
Common Stock
Gift
- Transaction value
- Shares
- -4,222
- Change %
- -3.5%
- Price
- $0.000000*
- Shares after
- 115,683
- Date
- 08 May 2026
- Ownership
- Direct
EW
transaction
Common Stock
Tax liability
- Transaction value
- Shares
- -5,398
- Change %
- -4.7%
- Price
- $82.76*
- Shares after
- 110,285
- Date
- 08 May 2026
- Ownership
- Direct
EW
transaction
Common Stock
Gift
- Transaction value
- Shares
- -5,489
- Change %
- -5%
- Price
- $0.000000*
- Shares after
- 104,796
- Date
- 11 May 2026
- Ownership
- Direct
EW
transaction
Common Stock
Gift
- Transaction value
- Shares
- +4,222
- Change %
- +35%
- Price
- $0.000000*
- Shares after
- 16,262
- Date
- 08 May 2026
- Ownership
- By Trust
EW
transaction
Common Stock
Gift
- Transaction value
- Shares
- +5,489
- Change %
- +34%
- Price
- $0.000000*
- Shares after
- 21,751
- Date
- 11 May 2026
- Ownership
- By Trust
EW
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 3,734
- Date
- 07 May 2026
- Ownership
- 401(k)
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EW
transaction
Derivative
Employee Stock Option (Right to Acquire)
Award
- Transaction value
- Shares
- +245,300
- Change %
- Price
- $0.000000*
- Shares after
- 245,300
- Date
- 07 May 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 245,300
- Exercise price
- $82.76
- Footnotes
- F2
EW
transaction
Derivative
Performance Rights
Award
- Transaction value
- Shares
- +43,800
- Change %
- Price
- $0.000000*
- Shares after
- 43,800
- Date
- 07 May 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 43,800
- Exercise price
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
Footnote F2
These options were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments.
Footnote F3
Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards.
SEC remarks
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.